Erythropoietin both protects from and reverses experimental diabetic neuropathy.
about
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesErythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathyNeuroprotective effect of erythropoietin against pressure ulcer in a mouse model of small fiber neuropathyTransforming growth factor-beta induces cellular injury in experimental diabetic neuropathyDevelopment of selective axonopathy in adult sensory neurons isolated from diabetic rats: role of glucose-induced oxidative stress.Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of cisplatin-induced neuropathy.Plant-Produced Asialo-Erythropoietin Restores Pancreatic Beta-Cell Function by Suppressing Mammalian Sterile-20-like Kinase (MST1) and Caspase-3 ActivationA nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injuryErythropoietin action in stress response, tissue maintenance and metabolism.Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid systemDarbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor.Early sustained injections of erythropoietin improve angiogenesis and restoration of perfusion in the ischemic mouse hindlimb.Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy.Diabetic neuropathy: new strategies for treatment.Two-step purification procedure for recombinant human asialoerythropoietin expressed in transgenic plants.Nitric oxide prevents axonal degeneration by inducing HIF-1-dependent expression of erythropoietin.Cytoprotective effect of recombinant human erythropoietin produced in transgenic tobacco plants.Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo.Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.Erythropoietin mediated bone formation is regulated by mTOR signaling.Erythropoietin accelerates functional recovery after peripheral nerve injury.Skin biopsy: a new tool for diagnosing peripheral neuropathy.Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.Metanx alleviates multiple manifestations of peripheral neuropathy and increases intraepidermal nerve fiber density in Zucker diabetic fatty rats.Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugsErythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID miceProtection of trigonelline on experimental diabetic peripheral neuropathy.Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot studyEndoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathyThe therapeutic potential of gene transfer for the treatment of peripheral neuropathies.Erythropoietic agents and the elderly.Epidermal nerve fiber quantification in the assessment of diabetic neuropathyErythropoietin and polyneuropathy in older persons12/15-Lipoxygenase inhibition counteracts MAPK phosphorylation in mouse and cell culture models of diabetic peripheral neuropathy.Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons.Gene therapy for the treatment of diabetic neuropathy.Functional magnetic resonance imaging of the spinal cord during sensory stimulation in diabetic ratsARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.Dietary hyperglycemia, glycemic index and metabolic retinal diseases.Schwann cells as a therapeutic target for peripheral neuropathies.
P2860
Q28388335-D4FA65BE-8F99-4D0A-90D8-E7F1B0A2BEEAQ28477706-A3B286B5-A3CA-485B-A101-14DFEC3632F3Q28545182-38569E5E-A1A8-44C9-9267-9407923BA2A0Q28575618-E79BD489-0D47-4470-B717-E398C6AE2571Q30487643-7BFC8AFB-CA59-488A-B962-9584C64CCDD9Q33482074-4B88C484-EB8B-4B72-A343-B7BD55342B8CQ33575974-335B9BC9-1772-49F8-A0B0-688BBCAC35EDQ33836284-B9F76704-BEB1-4879-9C55-CEAD1509100DQ33907747-3AE04D89-523C-4709-8F50-C282E56F09D8Q34100489-7A1D2C52-90DC-4E91-A89C-B985F7725F0CQ34219629-A4C04976-B984-47AE-A6A1-9B4A35AC333AQ34411778-02DEA2F0-F527-4ABF-983C-126E5C2FA935Q34626341-010F7133-B983-49EA-8879-01C76B12154AQ34641965-56BA3DCF-9D57-4A25-9CA3-9DB303F5BB04Q34663742-55AA5267-CE37-44FC-9819-9C5D5A317ACFQ34720972-4EA8E215-FBA9-42AC-B514-153BDD7CB71FQ35016979-F020DD23-6BF4-492F-A755-FF2A7495630CQ35113722-5A8F9A96-9811-40E9-93A9-3EEB3AC4E401Q35448895-DC0FA667-4689-4BA7-89EC-5C142D5D4F10Q35613027-E7336942-7D90-4691-9E62-308D9B4631C7Q35750138-925DDFA2-F3B2-4289-A48D-2911A458DA57Q35828193-C8BCFA60-5064-4F44-BB38-5C97043DF252Q35891811-354B9BBB-2AAD-48DA-B239-78267267C9C7Q36109233-2638378D-044E-41EA-8F0A-3179FA6C40FFQ36137260-C1FA7C57-6A7B-4356-BF3E-4C036B9CEE84Q36445059-364632DD-94EA-477C-98A1-35400E2F859EQ36477770-C49DF15D-1B6C-4492-A408-04276A30BA3FQ36585607-4AED4ED6-00C8-49DD-B257-AC412F07139EQ36635295-659AECEF-B669-44D7-9430-025BABC6E960Q36762639-CD99E7EE-E83A-42FB-B07C-2AC845A65064Q37098040-83113F80-18C6-47FD-9896-900596DBE0E5Q37126902-FE706829-C133-459C-BD43-988C10ACA692Q37174891-F0E799CD-EBFE-4EF0-BFC5-536B408D5CBFQ37257009-E4650D1B-4DF8-4981-B4C7-D35723FF86D0Q37300232-5E3459EB-CBF2-4EE9-833D-187A6744015AQ37319721-06335FA5-7F79-4873-A78A-4008D5EAB50DQ37343591-D058DC00-39C8-44E0-A044-1EFE451EC40AQ37446047-C16957C1-43B4-4D65-BBE9-07B2C98067B6Q37733102-B9E2A46C-BDBD-4D5B-BC90-8E286F61E2FDQ37793315-BEAB3B0C-FA59-4135-B9C6-5B06AC7DF568
P2860
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
@ast
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
@en
type
label
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
@ast
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
@en
prefLabel
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
@ast
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
@en
P2093
P2860
P50
P356
P1476
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
@en
P2093
Anthony Cerami
Arzu Kanik
Belgin Buyukakilli
Burak Cimen
Cengiz Tataroglu
Costanza Savino
Monica Borgna
Norberto Oggioni
Raffaella Lombardi
Roberto Bianchi
P2860
P304
P356
10.1073/PNAS.0307823100
P407
P577
2004-01-12T00:00:00Z